Role of Endothelin-1 and Thromboxane A2 in the Pulmonary Hypertension Induced by Heparin-Protamine Interaction in Anesthetized Dogs

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 1, 2004, Pages 106-112

  Freitas, Cristiane F ^a   Faro, Renato ^a   Dragosavac, Desanka ^b   Clozel, Martine ^b   De Nucci, Gilberto ^a   Antunes, Edson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Dazoxiben; Endothelin 1; Inhaled nitric oxide; Protamine; Pulmonary hypertension; Tezosentan

Indexed keywords

DAZOXIBEN; ENDOTHELIN 1; HEPARIN; INDOMETACIN; PROTAMINE; TEZOSENTAN; THROMBOXANE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; HEART CATHETERIZATION; LUNG ARTERY PRESSURE; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; MEDIATOR RELEASE; NONHUMAN; PRESSURE GRADIENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

ADMINISTRATION, INHALATION; ANIMALS; DOGS; ENDOTHELIN-1; FEMALE; HEPARIN ANTAGONISTS; HYPERTENSION, PULMONARY; MALE; NITRIC OXIDE; PROTAMINES; THROMBOXANE A2; THROMBOXANE B2;

EID: 0346333124     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200401000-00016     Document Type: Article

References (50)

1. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther. 2001;92:1-20.
2. Lowenstein E, Johnston WE, Lappas DG, et al. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology. 1983;59:470-473.
3. Katz NM, Kim YD, Siegelman R, et al. Hemodynamics of protamine administration. Comparison of right atrial, left atrial, and aortic injections. J Thorac Cardiovasc Surg. 1987;94:881-886.
4. Montalescot G, Lowenstein E. Ogletree ML, et al. Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep. Circulation. 1990;82:1765-1777.
5. Carr JAM, Silverman N. The heparin-protamine interaction. J Cardiovasc Surg. 1999;40:659-666.
6. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. N Engl J Med. 1992;327:117-119.
7. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
8. Tsutalnoto T, Wada AL, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427-1433.
9. Deuchar GA, Docherty A, MacLean MR, et al. Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone. Br J Pharmacol. 2002;135:1060-1068.
10. Earley S, Nelin LD, Chicoine LG, et al. Hypoxia-induced pulmonary endothelin-1 expression is unaltered by nitric oxido. J Appl Physiol. 2002;92:1152-1158.
11. Janakidevi K, Fisher MA, Del Vecchio PJ, et al. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol. 1992;263:C1295-C1301.
12. McDonald JW, Ali M, Morgan E, et al. Thromboxane synthesis by sources other than platelets in association with complement-induced pulmonary leukostasis and pulmonary hypertension in sheep. Circ Res. 1983;52:1-6.
13. Morel DR, Lowenstein E, Nguyenduy T, et al. Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep. Evidence for the role of reactive oxygen metabolites following non-immunological complement activation. Circ Res. 1988;62:905-915.
14. Hobbhahn J, Habazettl H, Conzen P, et al. Complications caused by protamine. 2. Therapy and prevention. Anaesthesist. 1991;40:421-428.
15. Wakefield TW, Bouffard JA, Spaulding SA, et al. Sequestration of platelets in the pulmonary circulation as a consequence of protamine reversal of the anticoagulant effects of heparin. J Vase Surg. 1987;5:187-193.
16. Sogawa M, Mohammad SF. Involvement of fibrinogen in protamine-induced pulmonary hypertension. J Surg Rev. 1997;73:80-84.
17. Morel DR, Zapol WM, Thomas SJ, et al. C5a and thromboxane generation associated with pulmonary vaso- and bronchoconstriction during protamine reversal of heparin. Anesthesiology. 1987;66:597-604.
18. Weiss ME, Nyhan D, Peng ZK, et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med. 1989;320:886-892.
19. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet. 1991;;338:1173-1174.
20. Frostell CG, Fratacci MD, Wain JCG, et al. Inhaled nitric oxide: A selectively pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 1991;83:2038-2047.
21. Hayward CS, MacDonald PS, Keogh AM. Inhaled nitric oxide in cardiology. Exp Opin Investig Drug. 2001;10:1947-1956.
22. Horrow JC. Protamine: a review of its toxicity. Anesth Analg. 1985;64:348-361.
23. Stefaniszyn HJ, Novick RJ, Salerno TA. Toward a better understanding of the hemodynamic effects of protamine and heparin interaction. J Thorac Cardiovasc Surg. 1984;87:678-686.
24. Horiguchi T, Enzan K, Mitsuhata H, et al. Heparin-protamine complexes cause pulmonary hypertension in goats. Anesthesioly. 1995;83:786-791.
25. Montalescot G, Fischman AJ, Strauss HW, et al. Imaging the ovine heparin-protamine interaction with I I I In-protamine. Appl Psysiol. 1993;75:963-971.
26. 2 release from the lung. Am J Surg. 1987;154:696-699.
27. Conzen PF, Habazettl H, Gutmann R, et al. Thromboxane mediation of pulmonary hemodynamic responses after neutralization of heparin by protamine in pigs. Anesth Analg. 1989;68:25-31.
28. Habazettl H, Conzen PF, Vollmar B, et al. Pulmonary hypertension after heparin-protamine: roles of left-sided infusion, histamine, and platelet-activating factor. Anesth Analg. 1990;71:637-644.
29. Nuttall GA, Murray MJ, Walter-Bowie EJ. Protamine-heparin-induced pulmonary hypertension in pigs: effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation. Anesthesiology. 1991;74:138-145.
30. Mizutani T, Takahashi S, Kihara S, et al. Effects of a thromboxane receptor antagonist (NT-126) and a thromboxane synthase inhibitor (OKY-046) on protamine-induced circulatory changes in dogs. J Cardiothorac Vase Anesth. 2000;14:687-692.
31. MacLean RM. Endothelin-1: a mediator of pulmonary hypertension? Pulmon Pharmacol Therap. 1998;11:132.
32. Stewart DJ, Kubac G, Costello KB, et al. Increased plasmaendothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
33. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation. 1991;84:2280-2285.
34. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001;14:833S-89S.
35. Clozel M, Ramuz H, Clozel JP, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther. 1999;290:840-846.
36. A-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol. 1995;269:L690-L697.
37. Coe Y, Haleen SJ, Welch KM, et al. The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb. J Pharmacol Exp Ther. 2002;302:672-680.
38. Tanus-Santos JE, Gordo WM, Udelsmann A, et al. The hemodynamic effects of endothelin receptor antagonism during a venous air infusion in dogs. Anesth Analg. 2000;90:102-106.
39. A antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation. 2001;103:314-318.
40. 2 increases the vasoconstrictor effect of endothelin-1 in postischemic reperfused rat hearts. Circulation. 1996;94:742-747.
41. 2 receptor in the vasoconstrictor response of rat aorta to endothelin. J Pharmacol Exp Ther. 1990;252:915-921.
42. Takayasu-Okishio M, Terashita Z, et al. Endothelin-1 and platelet activating factor stimulate thromboxane A2 biosynthesis in rat vascular smooth muscle cells. Biochem Pharmacol. 1990;40:2713-2717.
43. Vila JM, Martinez-Leon JB, Medina P, et al. U-46619-induced potentiation of noradrenergic constriction in the human saphenous vein: antagonism by thromboxane receptor blockade. Cardiovasc Res. 2001;52:462-467.
44. 2 mimetic in rat heart smooth muscle cells. Biochim Biopbys Acta. 1996;1313:1-5.
45. Tilton RG, Brock TA, Dixon RA. Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. Exp Opin Investig Drugs. 2001;10:1291-1308.
46. Rossi GP, Seccia TM, Nussdorfer GG. Reciprocal regulation of endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Inv Rev Cytol. 2001;209:241-272.
47. Brady AJB, Warren JB, Poole-Wilson PA, et al. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol. 1993;265:H176-H182.
48. Node K, Kitakaze M, Kosaka H, et al. Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction. Circulation. 1996;93:356-364.
49. Brady AJB, Poole-Wilson PA, Harding SE, et al. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol. 1992;263:H1963-H1966.
50. 1: effect on left ventricular contractility when used for treatment of experimental pulmonary hypertension. Eur J Cardiothorac Surg. 1998;14:494-502.